Therapeutic target: Targeting TPD52/TPD52L2 enhances the chemotherapeutic (docetaxel/rapamycin) response and synergizes with immunotherapy, suggesting novel GC treatment strategies. Here, TPD52L2 is linked to gastric cancer.